NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.01
+4.76%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -43.6%
- EBIT
- -11.9%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +40.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -12.5%
- EBIT
- -11.9%
- Net income
- -9.0%
- EPS
- +20.0%
- Free cash flow
- +24.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025